Priority-driven Collaborative Cancer Research Scheme 2012

Cancer Australia; Australian Rotary Health; Cancer Council Australia; Cancer Council New South Wales; Cure Cancer Australia Foundation; National Breast Cancer Foundation; and Prostate Cancer Foundation of Australia, are pleased to announce applicants who have been recommended for funding in the 2012 Round of the Priority-driven Collaborative Cancer Research Scheme.

Beaumont, Kimberley
Centenary Institute of Cancer Medicine and Cell Biology
The role of Rab27a and Rab5a in melanoma phenotype switching
Funded by Cure Cancer Australia Foundation

Bowden, Nikola
University of Newcastle
Investigation of the nucleotide excision repair pathway for melanoma biomarkers
Funded by Cure Cancer Australia Foundation

Buchanan, Daniel
Queensland Institute of Medical Research
Germline copy number variants are genetic risk factors for familial colorectal cancer
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Butler, Lisa
University of Adelaide
A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer
Co-funded by Prostate Cancer Foundation of Australia and Cancer Australia

Colvin, Emily
Kolling Institute of Medical Research
Investigating the tumour-promoting phenotype of cancer-associated fibroblasts in serous epithelial ovarian cancer
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Friedlander, Michael
The Prince of Wales Hospital
ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer
Co-funded by Cancer Council Australia and Cancer Australia – gynaecological cancers program

Georgy Smitha
Monash University
The role of mammalian transcription factor Grainyhead-like 3 in oesophageal cancer
Funded by Cure Cancer Australia Foundation
Grimison, Peter  
University of Sydney  
Accelerating first-line chemotherapy to improve cure rates for advanced germ cell tumours: an Australian-led, international randomised trial  
Funded by Cancer Australia

Hayne, Dickon  
University of Western Australia  
Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial  
Funded by Cancer Australia

Hong, Angela  
University of Sydney  
Improving the outcomes of oropharyngeal cancer: specific human papillomavirus oncoproteins and p53 mutations as modifying factors  
Funded by Cure Cancer Australia Foundation

Hutchinson, Andrew  
University of Technology Sydney  
Molecular characterisation and evaluation of neutral sphingomyelinase 2 as a novel target in multiple myeloma  
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Janda, Monika  
Queensland University of Technology  
Mirena ± Weight Loss to treat early Endometrial Cancer: (MAxWEL Trial)  
Funded by Cancer Australia– gynaecological cancers program

Jayachandran, Aparna  
Ludwig Institute for Cancer Research  
Hitting a moving target – overcoming invasion and resistance mechanisms by understanding melanoma plasticity using a combination of pre-clinical models  
Funded by Cure Cancer Australia Foundation

Jin, Feng  
The Kirby Institute  
Testing of biomarkers of human papillomavirus on anal cytology in homosexual men to predict the presence of high-grade anal intraepithelial neoplasia and its progression and persistence  
Funded by Cure Cancer Australia Foundation

Lucas, Robyn  
Australian National University  
Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency  
Funded by Cancer Australia

Micklethwaite, Kenneth  
Westmead Hospital  
Production of off the shelf T-cells expressing a non-MHC restricted CD19 specific chimeric antigen receptor for use in a Phase I study of T-cell therapy of relapsed and refractory B cell malignancies (UNI-T Study)  
Co-funded by Cure Cancer Australia Foundation and Cancer Australia
Mielke, Lisa
Walter and Eliza Hall Institute of Medical Research
*Innate immune cell protection and colon cancer*
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Morton, Rachael
University of Sydney
*The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modelled economic evaluation*
Funded by Cancer Australia

Moujalled, Donia
Walter and Eliza Hall Institute of Medical Research
*Mechanisms of RIPK3 activation by TNFR1*
Funded by Cure Cancer Australia Foundation

Nunez de Costa, Patricia
Austin Hospital
*The role of kinin receptors in liver regeneration and growth of colorectal liver metastases*
Funded by Cure Cancer Australia Foundation

O’Reilly, Lorraine
Walter and Eliza Hall Institute of Medical Research
*Understanding the role of NF-κ B in the progression of gastric adenocarcinomas and assessment of new therapies*
Funded by Cancer Council NSW

Pangon, Laurent
Garvan Institute of Medical Research
*Characterising a new mode of regulation of the beta-catenin pathway in colorectal cancer*
Funded by Cure Cancer Australia Foundation

Payne, Richard
University of Sydney
*Preparation and evaluation of synthetic self-adjuvanting cancer vaccine candidates*
Funded by Cure Cancer Australia Foundation

Pearson, Sallie
University of Sydney
*The use and impact of high cost targeted cancer medicines: theory and reality*
Co-funded by National Breast Cancer Foundation and Cancer Australia

Perrow, Kara
University of Wollongong
*Development of bifunctional anti-uPA/Anti-HER-2 lipidic nanoparticles to target advanced breast cancer*
Funded by Cure Cancer Australia Foundation

Price, Timothy
The Queen Elizabeth Hospital
*PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer*
Funded by Cancer Australia
Pritchard, Antonia
Queensland Institute of Medical Research
Identification of novel tumour epitopes as targets for immunotherapy
Funded by Cure Cancer Australia Foundation

Risbridger, Gail
Monash University
Defining epigenetic changes in prostate cancer stroma
Funded by Cancer Australia

Salmon, Jessica
Peter MacCallum Cancer Centre
Epigenetic therapies for the treatment of acute myeloid leukaemia
Funded by Cure Cancer Australia Foundation

Schofield, Penny
Peter MacCallum Cancer Centre
Solving Unknown Primary cancer – SUPER
Funded by Cancer Australia

Sjoquist, Katrin
University of Sydney
A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101)
Funded by Cancer Australia

Southey, Melissa
University of Melbourne
High risk genes for lobular breast cancer
Co-funded by National Breast Cancer Foundation and Cancer Australia

Tilley, Wayne
University of Adelaide
Mechanism and targeting of castration-resistant prostate cancer
Co-funded by Australian Rotary Health, Prostate Cancer Foundation of Australia and Cancer Australia

Tilley, Wayne
University of Adelaide
Targeting the androgen receptor in triple negative breast cancer
Co-funded by National Breast Cancer Foundation and Cancer Australia

Tomlinson, Christopher
Children’s Medical Research Institute
Investigating the mechanism of action of the cancer-associated enzyme telomerase using disease linked telomerase mutants
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Ugalde, Anna
Peter MacCallum Cancer Centre
The role and contribution of Australia’s cancer caregivers
Funded by Cure Cancer Australia Foundation
Waithman, Jason
Telethon Institute for Child Health Research
*Induction of adaptive immunity during melanoma*
Funded by Cure Cancer Australia Foundation

Weigmans, Adrian
Queensland Institute of Medical Research
*RAD51 overexpression regulates pro-metastatic gene expression profiles of aggressive metastatic triple negative breast cancer*
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Zheng, Yu
Garvan Institute of Medical Research
*Mechanisms of self-amplification and tumour growth in breast and prostate cancer metastases to bone*
Funded by Cure Cancer Australia Foundation